183 related articles for article (PubMed ID: 17538174)
1. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas.
Birrer MJ; Johnson ME; Hao K; Wong KK; Park DC; Bell A; Welch WR; Berkowitz RS; Mok SC
J Clin Oncol; 2007 Jun; 25(16):2281-7. PubMed ID: 17538174
[TBL] [Abstract][Full Text] [Related]
2. Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform.
Tsuda H; Birrer MJ; Ito YM; Ohashi Y; Lin M; Lee C; Wong WH; Rao PH; Lau CC; Berkowitz RS; Wong KK; Mok SC
Cancer Genet Cytogenet; 2004 Dec; 155(2):97-107. PubMed ID: 15571795
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
Yoshihara K; Tajima A; Komata D; Yamamoto T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Inoue I; Tanaka K
Cancer Sci; 2009 Aug; 100(8):1421-8. PubMed ID: 19486012
[TBL] [Abstract][Full Text] [Related]
4. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
Nanjundan M; Nakayama Y; Cheng KW; Lahad J; Liu J; Lu K; Kuo WL; Smith-McCune K; Fishman D; Gray JW; Mills GB
Cancer Res; 2007 Apr; 67(7):3074-84. PubMed ID: 17409414
[TBL] [Abstract][Full Text] [Related]
5. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
Meinhold-Heerlein I; Bauerschlag D; Hilpert F; Dimitrov P; Sapinoso LM; Orlowska-Volk M; Bauknecht T; Park TW; Jonat W; Jacobsen A; Sehouli J; Luttges J; Krajewski M; Krajewski S; Reed JC; Arnold N; Hampton GM
Oncogene; 2005 Feb; 24(6):1053-65. PubMed ID: 15558012
[TBL] [Abstract][Full Text] [Related]
6. BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer.
Le Page C; Ouellet V; Quinn MC; Tonin PN; Provencher DM; Mes-Masson AM
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):913-20. PubMed ID: 18398031
[TBL] [Abstract][Full Text] [Related]
7. Integrative analysis of copy number alteration and gene expression profiling in ovarian clear cell adenocarcinoma.
Sung CO; Choi CH; Ko YH; Ju H; Choi YL; Kim N; Kang SY; Ha SY; Choi K; Bae DS; Lee JW; Kim TJ; Song SY; Kim BG
Cancer Genet; 2013 May; 206(5):145-53. PubMed ID: 23726144
[TBL] [Abstract][Full Text] [Related]
8. Basic fibroblast growth factor and receptor expression in human ovarian cancer.
Crickard K; Gross JL; Crickard U; Yoonessi M; Lele S; Herblin WF; Eidsvoog K
Gynecol Oncol; 1994 Nov; 55(2):277-84. PubMed ID: 7959296
[TBL] [Abstract][Full Text] [Related]
9. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.
Mendrzyk F; Korshunov A; Benner A; Toedt G; Pfister S; Radlwimmer B; Lichter P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2070-9. PubMed ID: 16609018
[TBL] [Abstract][Full Text] [Related]
10. Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer.
Tominaga E; Tsuda H; Arao T; Nishimura S; Takano M; Kataoka F; Nomura H; Hirasawa A; Aoki D; Nishio K
Gynecol Oncol; 2010 Aug; 118(2):160-6. PubMed ID: 20537689
[TBL] [Abstract][Full Text] [Related]
11. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer.
Sunde JS; Donninger H; Wu K; Johnson ME; Pestell RG; Rose GS; Mok SC; Brady J; Bonome T; Birrer MJ
Cancer Res; 2006 Sep; 66(17):8404-12. PubMed ID: 16951150
[TBL] [Abstract][Full Text] [Related]
12. Array comparative genomic hybridization, expression array, and protein analysis of critical regions on chromosome arms 1q, 7q, and 8p in adenocarcinomas of the gastroesophageal junction.
van Dekken H; Tilanus HW; Hop WC; Dinjens WN; Wink JC; Vissers KJ; van Marion R
Cancer Genet Cytogenet; 2009 Feb; 189(1):37-42. PubMed ID: 19167610
[TBL] [Abstract][Full Text] [Related]
13. Depot-specific expression of fibroblast growth factors in human adipose tissue.
Gabrielsson BG; Johansson JM; Jennische E; Jernås M; Itoh Y; Peltonen M; Olbers T; Lönn L; Lönroth H; Sjöström L; Carlsson B; Carlsson LM; Lönn M
Obes Res; 2002 Jul; 10(7):608-16. PubMed ID: 12105282
[TBL] [Abstract][Full Text] [Related]
14. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
[TBL] [Abstract][Full Text] [Related]
15. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
[TBL] [Abstract][Full Text] [Related]
16. Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer.
Davis SJ; Sheppard KE; Pearson RB; Campbell IG; Gorringe KL; Simpson KJ
Clin Cancer Res; 2013 Mar; 19(6):1411-21. PubMed ID: 23362323
[TBL] [Abstract][Full Text] [Related]
17. Effects of degenerate oligonucleotide-primed polymerase chain reaction amplification and labeling methods on the sensitivity and specificity of metaphase- and array-based comparative genomic hybridization.
Tsubosa Y; Sugihara H; Mukaisho K; Kamitani S; Peng DF; Ling ZQ; Tani T; Hattori T
Cancer Genet Cytogenet; 2005 Apr; 158(2):156-66. PubMed ID: 15796963
[TBL] [Abstract][Full Text] [Related]
18. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer.
Kloth JN; Oosting J; van Wezel T; Szuhai K; Knijnenburg J; Gorter A; Kenter GG; Fleuren GJ; Jordanova ES
BMC Genomics; 2007 Feb; 8():53. PubMed ID: 17311676
[TBL] [Abstract][Full Text] [Related]
19. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
[TBL] [Abstract][Full Text] [Related]
20. Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas.
Miller CT; Aggarwal S; Lin TK; Dagenais SL; Contreras JI; Orringer MB; Glover TW; Beer DG; Lin L
Cancer Res; 2003 Jul; 63(14):4136-43. PubMed ID: 12874018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
